Summary of OmniAb Inc. Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: Q2 2026 revenue reached $13.4 million, a significant increase from $3.9 million in Q2 2025, primarily driven by higher milestone revenue from partner programs.

Year-to-Date Revenue: Total revenue for the first half of 2026 was $27.8 million, compared to $8.1 million in the same period last year.

Net Loss: The net loss improved to $5.9 million ($0.05 per share) in Q2 2026, down from $15.9 million ($0.15 per share) in Q2 2025. Year-to-date net loss was $13.6 million ($0.11 per share), compared to $34.1 million ($0.32 per share) in the prior year.

Cash Position: Cash balance at the end of Q2 was $52 million, bolstered by milestone payments.

Operating Expenses: Operating expenses remained flat year-over-year, with notable decreases in R&D and G&A expenses due to operational efficiencies.

2Strategic Updates and Business Highlights

Active Partners: OmniAb reported 110 active partners, including new licenses with EnRosa Therapeutics and argenx, a notable player in immunology.

Active Programs: The company has 425 active programs, with 34 in clinical trials, reflecting a healthy pipeline and potential for future revenue.

Technological Advancements: The launch of xPloration, a high-throughput single B cell screening platform, has generated interest, with two instruments sold in Q2. The platform is expected to diversify revenue streams.

Innovative Technologies: The company highlighted advancements in its antibody generation technologies, OmniUltra and OmnidAb, which are opening new markets and driving partner interest.

3Forward Guidance and Outlook

Revenue Guidance: OmniAb raised its 2026 revenue guidance to a range of $32 million to $36 million, primarily due to increased milestone achievements.

Operating Expenses: GAAP operating expenses are now expected to be between $84 million and $88 million, with cash operating expenses projected between $51 million and $55 million.

Cash Forecast: The company anticipates ending 2026 with cash and cash equivalents between $37 million and $41 million.

4Bad News, Challenges, or Points of Concern

Funding Gap: Despite the raised revenue guidance, there remains a projected gap of over $20 million between expected revenues and operating expenses, raising questions about future funding strategies.

Market Conditions: While the funding environment for biotech has improved, there is uncertainty regarding how quickly this will translate into increased revenue for OmniAb.

Variable Milestone Revenue: The company noted that milestone revenue can be highly variable, which may impact financial performance in subsequent quarters.

5Notable Q&A Insights

xPloration Utilization: Management expressed optimism about the xPloration platform's potential, though it is still early to assess its full impact on revenue and margins.

Partner Funding Dynamics: There is a belief that improved funding conditions in the biotech sector will lead to increased deal flow and partner engagement, particularly with smaller and emerging companies.

Growth in Preclinical Programs: The company has seen a positive trend in the progression of programs from discovery to clinical stages, with expectations for continued growth in the pipeline.

AI Integration: OmniAb is leveraging AI through its OmniDeep platform to enhance drug discovery processes, which is viewed as a significant competitive advantage. Overall, OmniAb Inc. demonstrated strong financial performance in Q2 2026, with positive developments in its partner programs and technology platforms, despite facing challenges related to funding and variable revenue streams. The outlook remains optimistic, supported by a robust pipeline and strategic initiatives.